Considerations for successful transplantation of encapsulated pancreatic islets

Diabetologia

Volumn 45, Issue 2, 2002, Pages 159-173

  De Vos, P ^a   Hamel, A F ^a   Tatarkiewicz, K ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b JOSLIN DIABETES CENTER   (United States)

Author keywords

Encapsulated pancreatic islets; Transplantation

Indexed keywords

BIOCOMPATIBILITY; BLOOD VESSEL SHUNT; CELL ENCAPSULATION; CONFERENCE PAPER; DONOR; HUMAN; MICROCAPSULE; PANCREAS ISLET TRANSPLANTATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; SURGICAL APPROACH; SURGICAL TECHNIQUE; SURVIVAL; TECHNOLOGY; THROMBOSIS; TISSUE ENGINEERING;

ANIMALS; CAPSULES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; HUMANS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; TRANSPLANTATION, HETEROLOGOUS;

EID: 0036192342     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-001-0729-x     Document Type: Conference Paper

References (132)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
2. Pancreas and islet transplantation for patients with diabetes
3. Pancreas transplantation: A review
4. Renal transplantation for type II diabetic patients compared with type I diabetic patients and patients over 50 years old: A single-center experience
5. Cell culture on artificial capillaries: An approach to tissue growth in vitro
6. Beta cell culture on synthetic capillaries: An artificial endocrine pancreas
7. Islet immunoisolation: The use of hybrid artificial organs to prevent islet tissue rejection
8. A hybird artificial pancreas
9. The use, in diabetic rats and monkeys, of artificial capillary units containing cultured islets of Langerhans (artificial endocrine pancreas)
10. Treatment of severe diabetes mellitus for more than one year using a vascularized hybrid artificial pancreas
11. Implantable biohybrid artificial organs
12. Feasibility of small bore AV shunts for hybrid artificial organs in nonheparinized beagle dogs
13. Bioengineering in development of the hybrid artificial pancreas
14. Control of streptozotocin diabetes in Chinese hamsters by cultured mouse islet cells without immunosuppression: A preliminary report
15. Correction of diabetic nod mice with insulinomas implanted within Baxter immunoisolation devices
16. Xenogeneic humoral responses to islets transplanted in biohybrid diffusion chambers
17. Glucose control and long-term survival in biobreeding/Worcester rats after intraperitoneal implantation of hydrophilic macrobeads containing porcine islets without immunosuppression
18. Maintenance of normoglycaemia in diabetic mice by subcutaneous xenografts of encapsulated islets
19. Outcome of subcutaneous islet transplantation improved by a polymer device
20. Beneficial influence of glycaemic control upon the growth and function of transplanted islets
21. Protection of encapsulated human islets implanted without immunosuppression in patients with type I or type II diabetes and in nondiabetic control subjects
22. Function and survival of macroencapsulated syngeneic islets transplanted into streptozocin-diabetic mice
23. Number and volume of islets transplanted in immunobarrier devices
24. Reversal of hyperglycemia in mice after subcutaneous transplantation of macroencapsulated islets
25. Histocompatibility of semipermeable membranes for implantable diffusion devices (bioartificial pancreas)
26. An adaption of the transparant chamber technique to the mouse
27. Hydrogels for encapsulation of pancreatic islet cells
28. In vitro and in vivo studies of the properties of an artificial membrane for pancreatic islet encapsulation
29. A simple method for transplanting discordant islets into rats using alginate gel spheres
30. How fibroblasts and giant cells encapsulate implants: Considerations in design of glucose sensors
31. Pancreatic islet transplantation using membrane diffusion chambers
32. Poly(ethylene oxide)-grafted thermoplastic membranes for use as cellular hybrid bio-artificial organs in the central nervous system
33. Collagen gel matrix promotes islet cell proliferation
34. Intercellular communication and maintenance of islet cell mass- implications for islet transplantation
35. Successful xenotransplantation of a diffusion-based biohybrid artificial pancreas: A study using canine, bovine, and porcine islets
36. Perspectives in diabetes. Islet transplantation with immunoisolation
37. Encapsulated cell therapy
38. Encapsulated cell technology
39. A simple method for xenotransplanting cells and tissues into rats using uncoated alginate microreactors
40. Agarose microcapsule applied in islet xenografts (hamster to mouse)
41. The good, the bad and the obvious: 1993 Clemson Award for Basic Research-Keynote Lecture
42. Influence of corona surface treatment on the properties of an artificial membrane used for Langerhans islets encapsulation: Permeability and biocompatibility studies
43. Physicochemical and biological studies of coronatreated artificial membranes used for pancreatic islets encapsulation: Mechanism of diffusion and interface modification
44. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation
45. Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression
46. Transplantation of pancreatic islets contained in minimal volume microcapsules in diabetic high mammalians
47. Evaluation of graft-host response for various tissue sources and animal models
48. In vitro and in vivo performance of porcine islets encapsulated in interfacially photopolymerized poly(ethylene glycol) diacrylate membranes
49. Transplantation of alginate microcapsules: Generation of antibodies against alginates and encapsulated porcine islet-like cell clusters
50. Coherent microcapsules for pancreatic islet transplantation: A new approach for bioartificial pancreas
51. Large-scale production of Ba(2 +)-alginate-coated islets of Langerhans for immunoisolation
52. Microencapsulated transplantation of allogeneic islets into specifically presensitized recipients
53. Production of mitogen-contamination free alginates with variable ratios of mannuronic acid to guluronic acid by free flow electrophoresis
54. Insulin secretion in streptozotocin-diabetic rats transplanted with immunoisolated islets
55. Microencapsulation and transplantation of genetically engineered cells: A new approach to somatic gene therapy
56. In vitro kinetics of insulin release by microencapsulated rat islets: Effect of the size of the microcapsules
57. Microencapsulation of mammalian cells in a HEMA-MMA copolymer: Effects on capsule morphology and permeability
58. Factors influencing the adequacy of microencapsulation of rat pancreatic islets
59. Improved biocompatibility but limited graft survival after purification of alginate for microencapsulation of pancreatic islets
60. Evaluation of microencapsulated islets in agarose gel as bioartificial pancreas by studies of hormone secretion in culture and by xenotransplantation
61. Microencapsulation of neonatal porcine islets: Long-term reversal of diabetes in nude mice and in vitro protection from human complement mediated cytolysis
62. Assessment of insulin secretion in vitro from microencapsulated fetal porcine islet-like cell clusters and rat, mouse, and human pancreatic islets
63. Graft copolymer emulsions of sodium alginate with hydroxyalkyl methacrylates for microencapsulation
64. Advantages of microencapsulation as an immunoprotection method in the transplantation of pancreatic islets
65. Pancreatic islet transplantation. Experimental and clinical aspects
66. Microencapsulation of rat islets prolongs xenograft survival in diabetic mice
67. Studies on small (< 300 microns) microcapsules: II-Parameters governing the production of alginate beads by high voltage electrostatic pulses
68. Complete protection of islets against allorejection and autoimmunity by a simple barium-alginate membrane
69. Impaired glucose tolerance in recipients of an intraperitoneally implanted microencapsulated islet allograft is caused by the slow diffusion of insulin through the peritoneal membrane
70. Kinetics of intraperitoneally infused insulin in rats: Functional implications for the bioartificial pancreas
71. C-peptide responses after meal challenge in mice transplanted with microencapsulated rat islets
72. Biocompatibility issues
73. Microencapsulated islets as bioartificial endocrine pancreas
74. Microencapsulation of viable hepatocytes in HEMA-MMA microcapsules: A preliminary study
75. New multicomponent capsules for immunoisolation
76. Immunocompatibility and biocompatibility of cell delivery systems
77. Effect of alginate-polylysine-alginate microencapsulation on in vitro insulin release from rat pancreatic islets
78. Production of purified alginates suitable for use in immunoisolated transplantation
79. Alginate polylysine microcapsules as immune barrier: Permeability of cytokines and immunoglobulins over the capsule membrane
80. Poly(ethylene oxide)-graft-poly(L-lysine)copolymers to enhance the biocompatibility of poly(L-lysine)-alginate micocapsules membranes
81. Interaction of acid polysaccharides with polylysine enantiomers, conformation probe in solution
82. Interaction of alginate and pectins with cationic polypeptides
83. Alginate-polylysine microcapsules of controlled membrane molecular weight cutoff for mammalian cell culture engineering
84. A fluorescence method for the determination of the molecular weight cut-off of alginate-polylysine microcapsules
85. Host reaction against alginate-polylysine microcapsules containing living cells
86. Host reaction against empty alginate-polylysine microcapsules. Influence of preparation procedure
87. Obstacles in the application of microencapsulation in islet transplantation
88. Factors influencing the properties and performance of microcapsules for immunoprotection of pancreatic islets
89. Technology of mammalian cell encapsulation
90. Effect of the alginate composition on the biocompatibility of alginate-polylysine microcapsules
91. Why do microencapsulated islet grafts fail in the absence of fibrotic overgrowth?
92. Induction of cytokine production from human monocytes stimulated with alginate
93. The involvement of CD14 in stimulation of cytokine production by uronic acid polymers
94. Poly-L-lysine induces fibrosis on alginate microcapsules via the induction of cytokines
95. Association between capsule diameter, adequacy of encapsulation, and survival of microencapsulated rat islet allografts
96. The efficacy of intraperitoneal pancreatic islet isografts in the reversal of diabetes in rats
97. Insulin levels after portal and systemic insulin infusion differ in a dose-dependent fashion
98. Intermittent intraperitoneal implantation of islets in rat islet transplantation
99. Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats
100. Effect of external oxygen mass transfer resistances on viability of immunoisolated tissue
101. Rat islet isograft function. Effect of graft volume and transplantation site
102. Reinnervation of pancreatic islets and regulation of insulin secretion by hepatic sympathetic nerves after intraportal transplantation of islets into livers of diabetic rats
103. Intraportally transplanted pancreatic islets revascularized from hepatic arterial system
104. DNA replication in mouse pancreatic islets transplanted subcapsularly into the kidney or intraportally into the liver. Influence of unilateral nephrectomy or partial hepatectomy
105. Prolonged function of canine pancreatic fragments autotransplanted to the spleen by venous reflux
106. Intrasplenic islet isografts
107. Islet cell mass and the longevity of islet grafts in diabetic rats
108. Islet transplantation to the renal subcapsular space improves late complications in streptozotocin-diabetic rats
109. Insulin secretion by rat islet isografts of a defined endocrine volume after transplantation to three different sites
110. Upscaling the production of encapsulated islets
111. Efficacy of a prevascularized expanded polytetrafluoroethylene solid support system as a transplantation site for pancreatic islets
112. Heparin-binding growth factor 1 induces the formation of organoid neovascular structures in vivo
113. Site-directed neovessel formation in vivo
114. Long-term (> 3-year) insulin independence in a patient with pancreatic islet cell transplantation following upper abdominal exenteration and liver replacement for fibrolamellar hepatocellular carcinoma
115. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
116. Improved vascularization of planar membrane diffusion devices following continuous infusion of vascular endothelial growth factor
117. Vascular endothelial growth factor (VEGF) and its receptors
118. Vascular endothelial growth factors and angiogenesis
119. Lymphoid activation by different crude alginates and the effect of purification
120. Encapsulation of rat islets of langerhans prolongs xenograft survival in diabetic mice
121. Xenografts of rat islets into diabetic mice
122. Growth and function of the pancreatic B-cell in vitro. Effect of glucose, hormones and serum factors on mouse, rat and human pancreatic islets in organ culture
123. Humoral response to encapsulated islets
124. Immunoisolation: At a turning point
125. Alginate polylysine microcapsules as immune barrier: Permeability of cytokines and immunoglobulins over the capsule membrane
126. Summary and definitions
127. Immunoprotection of pancreatic islet grafts within artificial microcapsules
128. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice
129. Engineering pancreatic islets
130. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells
131. Chitosan as a matrix for mammalian cell encapsulation
132. Microencapsulation of CHO cells in a hydroxyethyl methacrylate- methyl methacrylate copolymer